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Staging forms the most important prognostic factor in (gastric)
cancer and is the basis for treatment decisions. The 4th edition of the
TNM classification of malignant tumours by the Union
Internationale contre le Cancer (UICC) (Hermanek and Sobin,
1987) and the General Rules for the Gastric Cancer Study in Surgery
and Pathology by the Japanese Research Society for Gastric Cancer
(JRSGC) (Kajitani, 1981; Aiko and Sasako, 1998; Japanese Gastric
Cancer Association, 1998) both are based on the location of
involved lymph nodes to categorize lymph node involvement.
Several investigators have proposed other classifications for lymph
node involvement not taking into account the location of the
involved nodes, but e.g. the number of involved nodes (Wu et al,
1996). N classifications separately for T1, T2 and T3 (Ichikura et al,
1993) for nodal metastatic rate <50% and ≥50% (Kodera et al, 1997)
or for ≤25% and >25% (Yu et al, 1997) have also been proposed. 
In 1997, the 5th edition of the TNM classification of malignant
tumours was published (Sobin and Wittekind, 1997). For gastric
cancer the main difference is the importance of the number of
involved lymph nodes instead of the location of the involved
(regional) lymph nodes. 
The purpose of the present paper is to compare both TNM
classifications for their practical usefulness and prognostic value 
by using data of the Dutch Gastric Cancer Trial (Bonenkamp 
et al, 1999). 
PATIENTS AND METHODS 
Patients 
A total of 1078 patients with gastric cancer were randomized in the
Dutch D1–D2 Gastric Cancer Trial between August 1989 and July
1993 and entered by 78 hospitals with 52 affiliated pathology labora-
tories. All institutions had obtained medical ethical approval. For
eligibility, histologically proven adenocarcinoma of the stomach
without clinical evidence of distant metastasis was required. Patients
had to be younger than 85 years and biologically suitable for D1 as
well as D2 dissection. Patients were excluded if they had previous or
co-existing malignancies or previous gastrectomy for benign disease. 
The lymph nodes were grouped into 4 levels (N1 to N4)
according to the guidelines of the JRSGC (Kajitani, 1981).
Patients were randomized to undergo a D1 or D2 dissection. D1
dissection included the lymph nodes directly attached to the
stomach, whereas D2 required additional dissection of the lymph
nodes belonging to the N2 tier. Details of the trial design are
published elsewhere (Bonenkamp et al, 1999). 
711 patients were resected with a curative intent with macro-
scopically completely removed tumour, without peritoneal spread
nor liver metastasis nor distant lymph node metastasis, as
confirmed by frozen section examination of a para-aortic lymph
node biopsy (lymph node station number 16). After pathological
examination, 14 of the ‘curatively’ operated patients appeared to
have distant lymph node metastasis: 2 in station 13, 2 in station 
14 and 11 patients in station 16. Of the remaining 697 patients, 
58 patients were considered to have had a R1 resection (micro-
scopical residual tumour): 20 because of positive cytology of
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abdominal washing, 35 due to resection-line involvement and 3
patients due to positive cytology as well as positive margins. In 5
of the remaining 639 R0 patients, no primary tumour could be
found and in one patient the T-stage could not be determined due
to inadequate specimen handling. The present report will therefore
be based on 633 patients, including 44 patients who died in the
post-operative phase (in-hospital death or within 30 days after
surgery), since the postoperative mortality was different between
the D1 and D2 group (15 versus 29 patients). Survival time was
calculated from the date of surgery until death or last follow-up
alive. The range in follow-up time of patients still alive was 6.0 to
10.2 years, with a median follow-up of 7.9 years. 
Classifications 
In Table 1, two classifications for lymph node staging are given.
The 5th TNM edition (1997) contains three changes with regard to
the 4th TNM (1987) classification: 
1. The hepatoduodenal lymph nodes (station 12) are now classi-
fied as regional lymph nodes instead of distant; 
2. Histological examination of a regional lymphadenectomy
specimen should include 15 or more lymph nodes to justify a
pN0 staging; 
3. The number of positive regional lymph nodes determines the
N stage (1–6 involved nodes; N1, 7–15 involved nodes: N2
and ≥16 positive nodes: N3). 
Due to the fact that not all our patients classified as N0 according to
the 1987 edition fulfilled the condition of 15 or more lymph nodes
examined, we had to create a Nx category, defined as: according the
1987 classification pN0, but <15 lymph nodes examined. The term
node-negative patient is used for all patients where no positive
nodes were found, irrespective of the number of examined lymph
nodes. In consequence, the term node-positive patient is used for all
patients where one or more positive lymph nodes have been found,
irrespective of the number of examined lymph nodes. 
The TNM stage grouping has changed as a result of the N
changes: all N3 patients are classified as stage IV and T4N1
patients were classified as stage IIIb in 1987, but as stage IV in
1997 (Table 2). As said before, we had to make additional to the
official 1997 TNM definitions, a Nx category and consequently an
‘unclassifiable’ TNM category for the node-negative patients with
<15 lymph nodes examined (TNMx). 
Statistics 
The χ2 test was applied to assess differences in the distribution of
patients among groups. The Mann-Whitney test was used for
comparison of continuous variables. Univariate survival analysis
was carried out by using the Kaplan-Meier method and differences
between groups were compared by the log-rank test. The Cox’s
proportional hazards model with forward stepwise regression was
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Table 1 The 1987 and 1997 UICC TNM classifications for lymph node
staging 
N UICC 1987 UICC 1987
stage 4th edition 5th edition 
N0 No regional lymph node Histological examination of a regional
metastasis lymphadenectomy specimen will
ordinarily include ≥15 lymph nodes 
N1 Metastasis in perigastric 1–6 regional lymph node metastases
lymph node(s) ≤ 3 cm of the 
edge of the primary tumour
N2 Metastasis in perigastric 7–15 regional lymph node
lymph node(s) > 3 cm from metastases 
the edge of the primary 
tumour or in lymph nodes 
along the left gastric, common 
hepatic, splenic or coeliac 
arteries
N3 – ≥16 regional lymph node metastases 
M1 Metastasis in hepatoduodenal, Metastasis in retropancreatic, 
retropancreatic, mesenteric or mesenteric or para-aortic nodes 
para-aortic nodes
UICC: Union Internationale contre le Cancer (Hermanek and Sobin, 1987;
Sobin and Wittekind, 1997). 
Table 2 TNM stage classifications according to the 1987 and 1997 UICC editions
Changes compared to 4th edition (1987); Nx: <15 negative regional nodes examined: x: unclassifiable.
TNM stage classification 1987
M0
M0
M1
M1
T1 Ia Ib II IV
Ib II IIIa IV
II IIIa IIIb IV
IIIa IIIb IV IV
IV IV IV IV
T2
T3
T4
N0 N1 N2
TNM stage classification 1997
M0
M1
T1 Ia Ib II IV
Ib II IIIa IV
II IIIa IIIb IV
IIIa IV IV IV
IV IV IV IV
T2
T3
T4
N0 N1 N2
M0
N3
x
x
x
x
IV
Nx
IV
IV
IV
IV
IV
M1
used for multivariate analyses taking into account the following
variables: age, gender, tumour location, differentiation grade, 
T stage, 1987 and 1997 lymph node status, resection type,
dissection type and splenectomy/pancreatectomy. Analyses were
performed with the Statistical Product and Service Solutions,
SPSS 9.0 for Windows, 1998, SPSS Inc., Chicago IL. 
RESULTS 
N stage 
In Table 3, the 1987 and 1997 N classifications are summarized and
compared. For only 185 (62%) of the 298 node negative patients
a minimum of 15 lymph nodes were retrieved. As a result, 113
patients could not be staged, which is 18% of the total 633; they are
reported under Nx. From the 213 former N1 patients, 20% migrated:
17% to N2 and 3% to N3. From the former N2 patients, 71%
moved: 56% to N1 and 15% to N3. Two patients from the M1 group
moved to a regional lymph node status, since station 12 became a
regional location: 1 patient moved to N3 and 1 patient to N2. From
the 236 new N1 patients, 28% came from N2 and from the N2
patients 51% came from N1. In total, 131 out of 335 of node positive
patients (39%) migrated to a lower (21%) or higher (18%) N status. 
The prognosis of the different N groups is illustrated in Figure
1. The 5-year survival rates in the 1987 N0, N1 and N2 groups
were 72%, 34% and 27%. The difference between N1 and N2 was
not significant. The 5-year survival in the N0, N1, N2, and N3
groups of the 1997 N staging was respectively 75%, 38%, 19%
and 8%. These curves imply that the new N stages are better
discriminators; prognosis between N1 and N2 was significantly
different (P = 0.0006). Both the N1 1987 as well as N2 1987 group
were significantly separated into new N 1997 groups (P = 0.0063,
respectively P < 0.0005). The new N 1997 groups on the contrary
are homogeneous with respect to their N 1987 components: they
do not significantly differ from each other (Figure 2). 
D1 vs. D2 dissection 
Our patient population consists of patients who underwent different
dissection types. According to the 1987 classification, a N1 status
corresponds with a D1 dissection and a N2 status with a D2 dissec-
tion. As a result the N status between the dissection groups was
significantly different (P < 0.0001), e.g. 32% of D2 patients were
N2, compared to only 8% of the D1 patients (Table 4). 
66 E Klein Kranenbarg et al
British Journal of Cancer (2001) 84(1), 64–71 © 2001 Cancer Research Campaign
1.0
0.8
0.6
0.4
0.2
0.0
0 2 4 6 8 10
P < 0.0001
P < 0.0001
P = 0.1077
N0 (n = 298)
N1 (n = 213)
N2 (n = 120)
Su
rv
iva
l
(A) N 1987
1.0
0.8
0.6
0.4
0.2
0.0
0 2 4 6 8 10
P < 0.0001
P = 0.0155
P = 0.0664
P < 0.0001
N0 (n = 185)
Nx (n = 113)
N1 (n = 236)
N2 (n = 73)
N3 (n = 26)
Su
rv
iva
l
(B) N 1997
P = 0.0006
Years since surgery
Figure 1 Survival in 633 patients, according to N 1987 stage (A) and N
1997 stage (B) 
Table 4 For 633 gastric cancer patients the N status according to the 4th (1987), the 5th official (1997) edition and the 5th
modified (1997) edition of the TNM classification 
1987 1997, official 1997, modified 
D1 D2 D1 D2 D1 D2 
n (%) n (%) n (%) n (%) n (%) n (%) 
N0 161 (48) 137 (46) 74 (22) 111 (38) 147 (44) 132 (45) 
N1 148 (44) 65 (22) 129 (38) 107 (36) 129 (38) 107 (36) 
N2 28 (8) 92 (31) 36 (11) 37 (12) 36 (11) 37 (12) 
N3 – – – – 11 (3) 15 (5) 11 (3) 15 (5) 
Nx – – – – 87 (26) 26 (9) 14 (4) 5 (2) 
M1 0 (0) 2 (0.3) – – – – – – – – 
Total 337 (100) 296 (100) 337 (100) 296 (100) 337 (100) 296 (100) 
P < 0.0001 P < 0.0001 P = 0.28 
% represent column percentages. 
1997, official classification: ≥ 15 lymph nodes need to be examined to justify a N0 status. 
1997, modified classification: ≥ 5 lymph nodes need to be examined to justify a N0 status. 
Table 3 Relationship between the 1987 and 1997 lymph node (N)
classifications in 633 gastric cancer patients 
N 1987 
Total N0 N1 N2 M1 
Total 633 298 213 120 2 
N0 185
N1 236 67 
N 1997 N2 73 37 1 
N3 26 7 18 1 
Nx 113 113
35
185
169
According to the 1997 classification, N stage was also different
between the two dissection groups: 87 out of 161 (54%) D1 node-
negative patients were classified as Nx, compared to only 26
(19%) D2 node-negative patients. This is due to the fact that the
median number of examined nodes was 15 in the D1 group and 27
in the D2 group (P < 0.0001). If the requirement of the number of
examined lymph nodes is neglected (N0 + Nx combined), there is
no statistical difference in N stage between the D1 and D2 group
(P = 0.58). The median number of positive lymph nodes on the
other hand was 4 in both dissection groups and not significantly
different. 
TNM stage 
The new N status also resulted in a new TNM stage (Table 5). As a
consequence of the Nx status, a TNMx group had to be created.
23% of the non-TNMx patients (120 out of 520) migrated to
another stage. From former stage IIIa 50% of patients moved: 25%
to stage II, 14% to stage IIIb and 11% to stage IV. From former
stage IIIb 69% of patients migrated: 45% to stage IIIa and 24% to
stage IV. In the 1987 edition, 10 patients were classified as stage
IV, compared to 35 patients in the new edition. 
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Figure 2 Survival in node positive patients, according to N 1987 stage (A and B) and N 1997 stage (C and D). In figure A, the curve for N3–97 (n = 7) is not
shown. In figure D, the curve for M1–87 (n = 1) is not shown 
Table 5 Relationship between the 1987 and 1997 TNM stage distribution in
633 gastric cancer patients 
TNM 1987 
Total Ia Ib II IIIa IIIb IV 
Total 633 143 155 157 123 45 10
la 91
lb 112 11
TNM ll 151 2 31
1997 llla 100 18 20 1
lllb 31 17
lV 35 2 13 11
x 113 52 52 8 1
91
101
118
61
14
9
Survival according to the old and new TNM stage distribution is
presented in Figure 3. The survival per stage group was quite
similar in both editions. The TNMx group had approximately the
same survival as the Ib group. The former stage II, IIIa and IIIb
groups are composed of significantly different patients as shown
by the new TNM stage distribution (P = 0.05, P = 0.15 and P =
0.02 respectively) (figures not shown). The new stage II, IIIA, IIIb
and IV groups are homogeneously composed of former stage II to
IV patients (data not shown; not significant). 
Prognostic factors 
We evaluated the two N classifications on the one side and on 
the other side a series of classical prognostic factors: age, gender,
T stage, differentiation grade and resection type. The stepwise
selection pointed to the N 1997 classification as being more prog-
nostic than the N 1987 classification and moreover N 1997 was
selected before all other variables. Of course, as soon as N 1997
was selected, the N 1987 classification did not have much addi-
tional prognostic power. But running the model without the N
1997 classification, the most important variable was the N 1987
classification. So N 1987 in itself is highly prognostic, but N 1997
is, according to this Cox’s regression analysis, superior (Table 6). 
The Nx group had independent prognostic value with RR = 1.69
(95% CI 1.17–2.45), indicating the importance of a minimum
requirement in the new classification. 
We also investigated the possibility of a different prognostic
value of the N 1997 classification for D1 and D2 separately. For
Nx patients, the prognostic value for D1 and D2 was the same
(RR = 1.73 respectively RR = 1.87). However, for patients with
N2 disease, the relative risk was 6.33 for D1 patients compared to
2.37 for D2 patients. For N3 patients, this difference was also
present: RR = 9.95 for D1 patients compared to RR = 4.03 for D2
patients. So it seems that the prognostic value of the N 1997 clas-
sification is more important for D1 patients than for D2 patients. In
addition, the model selected gender as a prognostic factor in D2
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Figure 3 Survival in 633 patients, according to TNM 1987 stage (A) and
TNM 1997 stage (B) 
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Figure 4 Survival in 298 node-negative patients separated by number of
examined lymph nodes 
Table 6 Relative risk and 95% confidence intervals for the fitted multivariate
model, in order of stepwise selection 
Variable n RR 95% CI P value 
N 1997 
N0 185 1 
Nx 113 1.69 1.17–2.45 0.0054 
N1 236 2.50 1.84–3.39 <0.0001 
N2 73 3.41 2.34–4.96 <0.0001 
N3 26 4.57 2.81–7.43 <0.0001 
Age 633 1.04 1.03–1.05 <0.0001 
T stage 
T1 181 1 
T2 308 1.55 1.14–2.11 0.0050 
T3 132 2.36 1.66–3.35 <0.0001 
T4 12 2.04 1.00–4.13 0.0487 
Resection type 
Partial 430 1 
Total 203 1.50 1.20–1.88 0.0005 
Gender 
Female 273 1 
Male 360 1.38 1.11–1.71 0.0033 
Differentiation 
Good 66 1 
Moderate 208 0.97 0.65–1.45 0.8946 
Poor 340 1.36 0.93–1.99 0.1155 
Undifferentiated 19 1.03 0.52–2.02 0.9373 
RR: Relative risk, adjusted for all other variables, CI: confidence interval. 
Dissection type, N 1987 and splenectomy/pancreatectomy were not selected
by the model.
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patients (RR = 1.65 for males), although this variable was not
selected in D1 patients. 
Cut-off point 
In our series, 38% of 298 node-negative patients had to be classi-
fied as Nx. A closer look at these patients showed that 92% of
these patients had T1 or T2 tumours. To overcome such a high
percentage of missing N stages, we have searched for a lower,
acceptable minimum number of harvested lymph nodes on the
basis of prognosis. In Figure 4, a curve is given for the 298 node-
negative patients according to the official 1997 UICC N classifica-
tion, requiring at least 15 examined lymph nodes in order to justify
the node-negative classification. 5-year survival for patients with
at least 15 negative nodes was 75%. For patients with 10–14 or
5–9 examined nodes the 5-year survival was still high at 74%
(NS). Modifying this rule to the requirement of the consecutive
examination of at least 5 negative lymph nodes to justify a N0
classification, led to only 19 unclassifiable patients, moreover with
a poor prognosis. The 279 patients who were N0 according to this
modified rule, had a prognosis very similar to the 185 official N0
patients. Cox regression analysis with this modified classification
showed that the N0 group with ≥15 examined lymph nodes had a
similar relative risk than the N0 group with 5–15 examined nega-
tive lymph nodes (RR = 1.46, 95% CI 0.98–2.18) was not statistic-
ally different. The modified Nx group still had a worse prognosis
with a relative risk of 2.48 (95% CI 1.36– 4.52) compared to the
N0 group with ≥15 examined lymph nodes. Thus, a modification
to ≥5 lymph nodes being examined to justify N0 led to only 19
patients out of 633 (3%) with missing N status or 6% of the node-
negative patients only. 
DISCUSSION 
TNM classifications partly based on the number of positive nodes
are already in use in many cancer types. The 1997 TNM classifica-
tion for gastric cancer has now adopted the number of involved
nodes for classifying nodal involvement. Several investigators had
already proposed these changes for many years (Kim et al,
1992,1995; Ichikura et al, 1993; Wu et al, 1996). In 1993, Ichikura
et al compared the JRSGC, the 4th TNM classification and the
number of nodes and concluded that patients with 1–3 positive
nodes had as good a prognosis as those without nodal involvement
when analysed per T-stage (Ichikura et al, 1993). A multivariate
analysis in patients with 4 or more positive nodes showed that the
number of positive nodes was the most important prognostic deter-
minant and that N stage (1987) was not significantly prognostic.
Authors from Korea also proposed the number of involved nodes
(0, 1–3 and 4) (Kim et al, 1995). Others have proposed to use
metastatic rate (Kodera et al, 1997; Yu et al, 1997). We also found
that the new TNM classification based on the number of positive
nodes gives better prognostic information than the old TNM clas-
sification based on location of positive nodes. In 1998, two
German groups (Hermanek et al, 1998; Roder et al, 1998) and one
Japanese group (Kodera et al, 1998) also concluded that the 1997
TNM classification had led to a better estimation of outcome. 
The second major change in the new TNM classification is the
requirement to examine at least 15 lymph nodes to classify a
patient as N0. In the Dutch gastric cancer trial, from which
our data were recruited, meticulous harvesting of lymph nodes 
was performed (Bunt et al, 1996). However, in 54% of the
node-negative patients in the D1 group less than 15 lymph nodes
were harvested; even in the D2 group, 19% of node-negative
patients did not fulfil the minimum requirement to justify the N0
status. This requirement led to a substantial number of unclassifi-
able patients, in this report denoted by Nx patients. We have inter-
preted the rules of ≥15 examined lymph nodes as an adequate
number to validate the absence of regional lymph node metastasis.
However, it is unclear whether 6 of 6 positive nodes represents Nx
or N1 in the 1997 TNM system. We interpreted it as N1, although
the true N stage is probably N2 or greater. In our series in fact, in
the D1 group we found 67 N1 patients (52%) and 7 N2 (19%)
patients with <15 examined nodes. In the D2 group, we found 18
N1 patients (17%) and 0 N2 patients with <15 examined nodes. 
Fortunately, we found no relation between dissection (D1 or
D2) and number of positive nodes. The German and Japanese
studies (Hermanek et al, 1998; Kodera et al, 1998) did not experi-
ence such problems: in the first German study (Hermanek et al,
1998) only 2% of patients were unclassifiable and therefore
excluded and 9% in the study performed by Roder et al (1998)
while it was not mentioned by the authors of the Japanese study
(Kodera et al, 1998). In 1999, 3 other Japanese groups showed the
superiority of the 1997 classification compared to the Japanese
classification, but they also excluded 19%, respectively 9% of the
patients who did not fulfil the criterion (Fujii et al, 1999; Ichikura
et al, 1999; Kato et al, 1999) In the series of two European groups,
however, the new TNM did not improve prognostic stratification
and they also excluded patients who did not undergo a D2 dissec-
tion (de Manzoni et al, 1999; Mendes-de-Almeida et al, 1999). In
summary, 6 out of 8 publications showed that the 1997 classifica-
tion was superior to the location classifications in predicting prog-
nosis of patients. Yet, none of the authors debated the number of
15 nodes. In contrast to our series, all investigators presented
results on single institution or academic cohorts, where an
extended lymphadenectomy (D2) is standard of care. Our group
was composed of patients entered by 78 different, mainly non-
academic hospitals, and therefore more representative for daily
practice, at least in The Netherlands, although the trial focus was
on lymph nodes, so daily practice might even be worse. In the trial,
the nodes were removed by a specially trained study coordinator
or by one of the 8 supervising surgeons. They divided the perigas-
tric tissue into proper lymph node stations. Afterwards, the tissue
was examined further by the pathologist, using the conventional
technique, i.e. lamellation and palpation of the specimen. 
In a publication on an US gastric adjuvant protocol no statement
regarding the lymph nodes was made in 17% of cases, D0 resec-
tions were performed in 54% of patients and in 45% of patients
less than 11 lymph nodes had been removed. In these patients,
45% of lymph nodes was found to be positive, compared to only
13% when more than 40 nodes were removed, thus the greater 
the chance of resecting to a level of negative lymphatic (Estes 
et al, 1998). 
The rationale for the examination of at least 15 nodes is based
on two German reports (Hermanek, 1991; Wagner et al, 1991).
Firstly, Wagner and colleagues (Wagner et al, 1991) determined
the number of regional lymph nodes indicated by the JRSGC in 30
non-cancer cadavers. They found 17–44 lymph nodes after a D2
dissection, with an average of 27 nodes and advocated the use of
these yields as normal reference values. In the cadaver study,
however, the tissue was cleared by dissolving fatty tissue, making
lymph nodes of 1 mm visible and a D2 dissection was performed,
both making the number for daily routine use extremely high. In a
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small number of patients in our study, we have also used the fat
clearance technique and found significantly more lymph nodes in
the D1 group (mean 25 versus 15, P < 0.01) compared to the
routinely used techniques (Bunt et al, 1996). Others have shown
that comprehensive fat-clearing doubled total lymph node counts,
identified smaller lymph nodes, and identified more histologically
involved nodes of smaller size and upstaged 29% of specimen
(Candela et al, 1990). 
Secondly, data from the Erlangen Cancer Center showed that
with an increasing number of examined regional lymph nodes a
higher incidence of proven node-positive cases and also a higher
5-year survival rate was observed (Hermanek, 1991). These find-
ings were confirmed by another German study (Siewert et al,
1993). They prospectively registered and analysed gastrectomies
with extended lymphadenectomies in 19 hospitals, of which 
16 were university hospitals and concluded that radical
lymphadenectomy (> 26 nodes) improved survival rate compared
to < 26 nodes. They concluded that a cut-off point of 15 lymph
nodes should be chosen where the prevalence of node-positive
patients did not depend on the number of examined lymph nodes
anymore. Since this was not a randomized study, it is not clear
why > 26 nodes were removed and results were not corrected for
potential bias. 
Our proposal is to modify the requirement of having at least 15
lymph nodes examined in order to justify a N0 classification into
the requirement of at least 5 lymph nodes. At this cut-off point,
only 6% of the node-negative patients would be unclassifiable
(Nx and TNMx), compared to 38% when using the 15 node
threshold. The lack of a survival difference between the modified
classification and the original classification supports this cut 
off point. Determination of a specified minimum number of
lymph nodes using conventional techniques was also studied in
colorectal patients where at least 12 nodes are required and it 
was found that at least 7 nodes should be examined (Caplin 
et al, 1998). 
The 1997 TNM classification does not make recommendations
on the techniques for the retrieval and examination of the nodes,
however fat-clearance (Candela et al, 1990) and lymph node
revealing solution (Koren et al, 1998) will increase the yield of
the number of examined nodes. Serial sectioning (Isozaki et al,
1997), immunohistochemical staining (Ishida et al, 1997) and
more recently reverse transciptase-polymerase chain reaction
(RT-PCR) (Mori et al, 1995) will increase the detection of occult
metastases. 
To comply with the rules of the TNM classification is hardly
feasible applying a D1 dissection. However, our recently
published long-term survival results of the randomized compar-
ison of D1 versus D2 dissection did not support the routine use of
D2: 5-year survival was 45% after D1 and 47% after D2 dissec-
tion. Moreover, cumulative relapse risk was not different: 43%
after D1 and 37% after D2 dissection (Bonenkamp et al, 1999).
Similar results were observed in a randomized MRC trial
comparing D1 and D2: no differences could be found concerning
overall survival, gastric cancer survival and recurrence-free
survival (Cuschieri et al, 1999). 
In conclusion, the 5th edition of the TNM classification
provides a better estimation of long-term survival, although the
cut-off point of at least 15 examined lymph nodes to justify a N0
status caused many unclassifiable patients in our nation-wide trial.
We propose the modification to use 5 lymph nodes as a reliable
minimum for staging purposes. 
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